← Who reports today · Health Care
Thermo Fisher Scientific (TMO) earnings date & Q3 2026 results
Net income attributable to Thermo Fisher Scientific Inc.
$1,721M
up 6.5% y/y
Revenues
$12,137M
up 9.1% y/y
Operating income
$2,263M
up 16.6% y/y
Next report
~ Jan 28
not announced yet
The quarter in brief
Revenue grew 9% to $12.14 billion with 6% organic growth, and GAAP operating income rose 17% to $2.26 billion; operating margin widened to 18.6% from 17.4%. Net income attributable to the company rose 6.5% to $1,721 million and diluted EPS grew 9% to $4.64 from $4.27.
Key growth driver: Amortization of acquisition-related intangibles rose to $519 million from $435 million, and interest expense increased to $417 million from $347 million. · by the Q3 2026 report
All figures in $M.
| Line item | Amount and change |
|---|---|
| Revenues | $12,137 · +9.1% |
| Cost of revenues | $6,945 · +7.3% |
| Selling, general and administrative expenses | $1,863 · +3.8% |
| Amortization of acquisition-related intangible assets | $519 · +19.3% |
| Research and development expenses | $348 · +0.6% |
| Restructuring and other costs | $199 · +47.4% |
| Operating income | $2,263 · +16.6% · 18.6% margin |
| Interest income | $252 · +7.7% |
| Interest expense | $417 · +20.2% |
| Other income/(expense) | $10 · +400% |
| Income before income taxes | $2,088 · +14.3% |
| Provision for income taxes | $352 · +70.0% · 16.9% effective rate |
| Equity in earnings/(losses) of unconsolidated entities | $9 · vs $2 |
| Net income attributable to noncontrolling interests | $6 · +20.0% |
| Net income attributable to Thermo Fisher Scientific Inc. | $1,721 · +6.5% · $4.64/sh · 14.2% margin |
Verdict: Revenue grew 9% to $12.14 billion with 6% organic growth, and GAAP operating income rose 17% to $2.26 billion; operating margin widened to 18.6% from 17.4%. Net income attributable to the company rose 6.5% to $1,721 million and diluted EPS grew 9% to $4.64 from $4.27.
In the first nine months of 2026 the company repurchased $4,000 million of its stock and paid $511 million in dividends. Third-quarter free cash flow was $2,115 million versus $1,840 million a year earlier.
Source and notation
Source: Thermo Fisher Scientific press release, 8-K EX-99.1 of 10/21/2026 (SEC EDGAR).
Open as an image: Thermo Fisher Scientific (TMO), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Thermo Fisher Scientific (TMO) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/tmo. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/tmo"><img src="https://whoreportstoday.com/t/tmo/img/thermo-fisher-scientific-tmo-earnings-sankey.png" alt="Thermo Fisher Scientific (TMO) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/tmo">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/tmo/img/thermo-fisher-scientific-tmo-earnings-sankey.png
<a href="https://whoreportstoday.com/t/tmo">Thermo Fisher Scientific (TMO) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Acquisitions/divestitures added 3% to revenue growth, currency added 0%, leaving 6% organic growth.
- Restructuring and other costs of $199 million included a $244 million held-for-sale loss and a $72 million gain on the sale of a business, versus $135 million a year earlier.
- Amortization of acquisition-related intangibles rose to $519 million from $435 million, and interest expense increased to $417 million from $347 million.
- The effective tax rate rose to 16.9% from 11.3%; net income grew only 6.5% versus 16.6% growth in operating income.
- Diluted share count fell to 371 million from 378 million, helping EPS grow 9% versus 6.5% for net income.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Marc N. CasperChairman and Chief Executive Officer [1]
- James R. MeyerSenior Vice President and Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Thermo Fisher Scientificsince 2006
- Chairman, President and Chief Executive Officernow
- President and Chief Executive Officer2009–2020
- Chief Operating Officer2008–2009
- Executive Vice President2006–2009
Source: SEC EDGAR: 10-K annual report, 2026-02-26 · as of 10/21/2026
- Thermo Fisher Scientificsince 2009
- Senior Vice President and CFOsince 2026
- Vice President, Financial Operations2023–2026
- Vice President of Finance, Customer Channels2020–2022
- Finance roles2009
- PricewaterhouseCoopersuntil 2009Roles
Source: SEC EDGAR: 8-K (appointment), 2025-07-23 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-10-30 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-10-30 · SEC EDGAR · 11/18/2026
Thermo Fisher Scientific Inc. is an American life science and clinical research company. · Text: Wikipedia, CC BY-SA 4.0, abridged
It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
Company reports
Company guidance
The company reaffirmed its outlook, no figures in the release.
Same quarter a year ago (ended December 31, 2025): revenue $12.21B, EPS (GAAP) $5.21
How we calculate
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Oct 21, 2026); every figure is checked against the release text.
TMO earnings history: past report dates
| Oct 21, 2026 Wed | 6:03 ambefore market open | Sep 26, 2026 | $12.1B+9% y/y | $4.64+9% y/y |
| Jul 23, 2026 Thu | 6:04 ambefore market open | Jun 27, 2026 | $12.0B+10% y/y | $4.68+9% y/y |
| Apr 23, 2026 Thu | 6:03 ambefore market open | Mar 28, 2026 | $11.0B+6% y/y | $4.43+11% y/y |
| Jan 29, 2026 Thu | 6:02 ambefore market open | Dec 31, 2025 | ≈$12.2B+7% y/y | ≈$5.21+9% y/y |
| Oct 22, 2025 Wed | 6:05 ambefore market open | Sep 27, 2025 | $11.1B+5% y/y | $4.27+0% y/y |
| Jul 23, 2025 Wed | 6:03 ambefore market open | Jun 28, 2025 | $10.9B+3% y/y | $4.28+6% y/y |
| Apr 23, 2025 Wed | 6:04 ambefore market open | Mar 29, 2025 | $10.4B+0% y/y | $3.98+15% y/y |
| Jan 30, 2025 Thu | 6:03 ambefore market open | Dec 31, 2024 | ≈$11.4B+5% y/y | ≈$4.78+14% y/y |
| Oct 23, 2024 Wed | 6:03 ambefore market open | Sep 28, 2024 | $10.6B+0% y/y | $4.25−4% y/y |
| Jul 24, 2024 Wed | 6:03 ambefore market open | Jun 29, 2024 | $10.5B−1% y/y | $4.04+15% y/y |
| Apr 24, 2024 Wed | 6:03 ambefore market open | Mar 30, 2024 | $10.3B−3% y/y | $3.46+4% y/y |
| Jan 31, 2024 Wed | 6:02 ambefore market open | Dec 31, 2023 | ≈$10.9B−5% y/y | ≈$4.20+5% y/y |
| Oct 25, 2023 Wed | 6:03 ambefore market open | Sep 30, 2023 | $10.6B−1% y/y | $4.42+17% y/y |
| Jul 26, 2023 Wed | 6:02 ambefore market open | Jul 1, 2023 | $10.7B−3% y/y | $3.51−17% y/y |
| Apr 26, 2023 Wed | 6:04 ambefore market open | Apr 1, 2023 | $10.7B−9% y/y | $3.32−41% y/y |
| Feb 1, 2023 Wed | 6:05 ambefore market open | Dec 31, 2022 | ≈$11.4B+7% y/y | ≈$4.01−4% y/y |
Show all 16 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Thermo Fisher Scientific: 15-year financials
| 2025 | 44,556 | 7,746 | 6,704 | 6,293 | 636 |
| 2024 | 42,879 | 7,337 | 6,335 | 7,267 | 583 |
| 2023 | 42,857 | 6,859 | 5,995 | 6,927 | 523 |
| 2022 | 44,915 | 8,393 | 6,950 | 6,911 | 455 |
| 2021 | 39,211 | 10,028 | 7,725 | 6,789 | 395 |
| 2020 | 32,218 | 7,794 | 6,375 | 6,815 | 337 |
| 2019 | 25,542 | 4,594 | 3,696 | 4,047 | 297 |
| 2018 | 24,358 | 3,783 | 2,938 | 3,785 | 266 |
| 2017 | 20,918 | 2,960 | 2,225 | 3,497 | 237 |
| 2016 | 18,274 | 2,458 | 2,022 | 2,814 | 238 |
| 2015 | 16,965 | 2,336 | 1,975 | 2,519 | 241 |
| 2014 | 16,890 | 2,503 | 1,894 | 2,192 | 235 |
| 2013 | 13,090 | 1,610 | 1,273 | 1,728 | 216 |
| 2012 | 12,510 | 1,482 | 1,178 | 1,724 | 142 |
| 2011 | 11,559 | 1,251 | 1,330 | 1,430 | 0 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Thermo Fisher Scientific: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 110,343 | 53,407 | 39,172 | 9,852 | 28,707 | 15,189 |
| 2024 | 97,321 | 49,584 | 31,072 | 4,009 | 22,137 | 13,332 |
| 2023 | 98,726 | 46,735 | 34,727 | 8,077 | 24,589 | 14,012 |
| 2022 | 97,154 | 43,978 | 34,278 | 8,524 | 25,229 | 17,010 |
| 2021 | 95,123 | 40,793 | 34,670 | 4,477 | 20,113 | 13,436 |
| 2020 | 69,052 | 34,507 | 21,728 | 10,325 | 21,957 | 10,304 |
| 2019 | 58,381 | 29,675 | 17,752 | 2,399 | 11,893 | 6,197 |
| 2018 | 56,232 | 27,586 | 19,683 | 2,103 | 10,625 | 6,147 |
| 2017 | 56,669 | 25,413 | 21,968 | 1,335 | 9,421 | 7,048 |
| 2016 | 45,908 | 21,540 | 17,580 | 786 | 7,021 | 4,866 |
| 2015 | 40,834 | 21,350 | 12,522 | 452 | 5,741 | 4,146 |
| 2014 | 42,852 | 20,548 | 14,564 | 1,344 | 6,540 | 5,350 |
| 2013 | 31,863 | 16,856 | 10,767 | 5,826 | 9,881 | 3,126 |
| 2012 | 27,445 | 15,465 | 7,124 | 806 | 4,835 | 2,093 |
| 2011 | 26,834 | 15,038 | 7,028 | 1,016 | 4,822 | 3,113 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-26 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 5,867 | 4,361 | +1,506 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 945 | 758 | |
| · incl. stock-based comp (non-cash)share-based compensation | 261 | 226 | |
| Capexpurchases of property & equipment | −1,263 | −1,060 | −203 |
| Free cash flow ≈operating cash flow − capex | 4,604 | 3,301 | +1,303 |
| Investing activities, netcapex, acquisitions, securities | −8,874 | −4,938 | −3,936 |
| · incl. acquisitionsbusinesses net of cash acquired | −8,877 | −4,037 | −4,840 |
| Financing activities, netdebt, buybacks, dividends | −1,541 | −1,725 | +184 |
| · incl. buybacksrepurchases of common stock | −4,000 | −2,963 | −1,037 |
| · incl. dividends paid | −511 | −474 | −37 |
| Net change in cash | −4,384 | −2,029 | −2,355 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 26, 2026: $54.8B (48% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Feb 202610-K FY2025 cover: a single class of common stock; Legal Proceedings lists only product, IP, employment and commercial claims — no shareholder suits and no SEC cases. sec.gov ↗
- Jan 2026Shares outstanding of 371.5M vs. 393.8M in February 2021 (−5.7% over 5 years); 2025 SBC of $310M, 0.7% of revenue. data.sec.gov ↗
1 more fact and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Dec 2025Dividend per share rose from $0.88 (2020) to $1.72 (2025); buybacks of $3–4B a year in 2022–2025. data.sec.gov ↗
Scoring: 2.0, no deductions: single share class, share count −5.7% over 5 years, SBC 0.7% of revenue, dividend raised every year, no shareholder suits or SEC cases = 2.0
- Share classes
- The 10-K cover registers a single class — Common Stock (NYSE: TMO); no deduction.
- Dilution
- Shares outstanding 393.8M (February 2021) → 371.5M (January 2026), −5.7%; SBC $310M = 0.7% of revenue; no deduction.
- Disclosure
- Full 10-K/10-Q reporting, filed on time.
- Dividends
- Dividend $0.88 (2020) → $1.72 (2025), raised every year; buybacks of $2–4B a year in 2021–2025; no policy breaches.
- Lawsuits & regulators
- Legal Proceedings in the 2025 10-K lists only product liability, IP, employment and commercial claims; no shareholder disclosure suits and no SEC cases.
- Related parties
- 2026 proxy: related-party transactions go through the audit committee, none material disclosed; no controlling shareholder.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Thermo Fisher Scientific (TMO) earnings: FAQ
When is TMO's next earnings date?
We have not yet seen an announcement of the date from Thermo Fisher Scientific (TMO). Based on last year's report on Jan 29, 2026, the next report is expected around Jan 28, 2027.
What time does TMO report earnings?
Thermo Fisher Scientific usually reports before market open: its latest results release was filed with the SEC at 6:03 am ET on Oct 21, 2026.
When did TMO last report earnings?
Thermo Fisher Scientific reported Q3 2026 results on Oct 21, 2026.
Where can I find Thermo Fisher Scientific's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to TMO's filings; this page breaks the latest report down in a Sankey chart.
What was TMO's net income in Q3 2026?
Thermo Fisher Scientific reported net income of $1,721M for Q3 2026 (+6.5% year over year), under US GAAP.
Does Thermo Fisher Scientific pay dividends?
Yes. In 2025, Thermo Fisher Scientific paid $636M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Thermo Fisher Scientific's revenue changed since 2011?
Per its 10-K filings, revenue grew 3.9x: $11,559M in 2011 and $44,556M in 2025. The peak was $44,915M in 2022. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: UHS · Q3 2026 · UNH · Q3 2026 · VEEV · Q2 FY2027 · VRTX · Q3 2026 · VTRS · Q2 2026 · WAT · Q3 2026 · WST · Q3 2026 · ZBH · Q3 2026 · ZTS · Q3 2026 · A · Q3 FY2026 · all reports